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INTRODUCTION: Liposarcoma is one of the most common soft tissue sarcomas; however, early diagnosis
is rare as the tumor remains difﬁcult and unpalpable for a prolonged period of time.
PRESENTATION OF CASE: Here we report the ﬁrst case of retroperitoneal liposarcoma associated with
pregnancy and expression of estrogen receptor. A 34-year-old woman experienced persistent abdom-
inal distension after her ﬁrst delivery. Computed tomography (CT) and magnetic resonance imaging
(MRI) revealed a large (40 cm×35 cm), solid, palpable abdominal mass with fat attenuation displacing
the ascending colon and the right kidney to the left. Laparotomy and an en-bloc resection of the tumor
were performed; further, right nephrectomy and adrenalectomy were required. Histopathology showed
a well-differentiated liposarcoma; approximately 10–20% of the tumor cells were ER-positive.
DISCUSSION: Retroperitoneal liposarcoma associated with pregnancy is an extremely rare occurrence.
Surgical resection is unquestionably the ﬁrst choice of treatment, but complete resection is sometimes
impossible due to the volume and depth of invasion of the tumor. In such cases, additional therapy for
liposarcoma is important to improve prognosis. Thus, this report highlights the need for further research
into hormone therapy.
CONCLUSION: Retroperitoneal liposarcoma has a high local recurrence rate due to the difﬁculty in com-
plete surgical resection; therefore, additional hormone therapy is important for improving the prognosis.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Background
Liposarcoma is one of the most common soft tissue sarcomas,
yet early diagnosis is rare because the tumor remains difﬁcult and
unpalpable for a prolonged period of time. The peak incidence of
liposarcoma occurs from 40 to 60 years of age with the prepon-
derance of cases reported in men [1]. It is very rare in females
of reproductive age, and the prognosis is better in pre-than in
post-menopausal women [2]. Although some reports mention an
association between steroid hormones and malignant soft tissue
tumors including liposarcomas, a case of liposarcoma associated
with pregnancy wherein hormone receptors have been investi-
gated has not been previously reported. Here, we report the ﬁrst
case of retroperitoneal liposarcoma associatedwith pregnancy and
ER expression and review the literature.
∗ Corresponding author. Tel.: +81 666453838, fax: +81 666466450.
E-mail address: m1165063@med.osaka-cu.ac.jp (H. Kasashima).
2. Case report
A 34-year-old woman experienced persistent abdominal dis-
tension for the duration of her pregnancy with no improvement
even after delivery. She had a normal delivery eightmonths earlier,
and her child displayed normal growth. Although no abnormalities
were detected during the several routine transvaginal ultrasono-
graphic examinations performed during pregnancy, at birth, and
six months after delivery, contrast enhanced computed tomogra-
phy (CT) and magnetic resonance imaging (MRI) (fat suppression,
T1WI) revealed a 40 cm×35 cm solid mass with fat attenuation
displacing the ascending colon and the right kidney to the left
(Fig. 1A and B). Furthermore, this was accompanied by breath-
lessness due to restriction of diaphragmaticmovement. Laboratory
ﬁndings including tumor marker CA-125, alpha-fetoprotein, and
carcino-embryogenic antigen levels werewithin the normal range.
Laparotomy was performed under general anesthesia, and a mass
was found to bewrapped in the retroperitoneumand pseudomem-
brane. The uterus, uterine tube and ovaries were normal. We
performed an en-bloc resection of the tumor, along with right
nephrectomy and adrenalectomy.
http://dx.doi.org/10.1016/j.ijscr.2015.01.002
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. (A) contrast enhanced CT, (B) MRI (fat suppression, T1WI) A 40×35 cm solid mass with fat attenuation displacing ascending colon and right kidney to left.
The retroperitoneal mass weighed 7200g and measured
43 cm×40 cm×13 cm (Fig. 2). Histopathological examination of
the surgical specimen showed a well-differentiated liposarcoma
(Fig. 3). Immunohistochemistry revealed approximately 10–20% of
the tumor cells to be estrogen receptor (ER)-positive, with nega-
tive results for the progesterone receptor (PR) (Fig. 4). The patient
recovered uneventfully and was discharged from the hospital on
the 15th postoperative day. She and her husband were planning to
try for another baby, so postoperative adjuvant therapy including
hormone therapywas not undertaken. No recurrencewas detected
at the 3-year follow-up.
3. Discussion
Retroperitoneal sarcomas represent approximately 10–15% of
all soft tissue sarcomas, which themselves are rare, accounting
for only 1% of all malignancy [3]. The peak incidence of liposar-
coma occurs from 40 to 60 years of age. The tumor is typically
aggressive, with reported 5-year survival rates ranging from only
23% to 46% [4]. Lewis et al. [5] reported high local recurrence
rates for retroperitoneal sarcoma, ranging from 40% to 80%. As the
retroperitoneal space is easily distended by the enlarging tumor,
theneoplasia remains inactiveandunpalpable forprolongedperiod
Fig. 2. Gross appearance of the tumor. An elastic soft mass covered pseudocapsule
weighed 7200g and measured 43 cm×40 cm×13 cm with lobulations.
of time. A retroperitoneal mass may produce a wide range of
signs and symptoms due to the compression and inﬁltration of
the surrounding organs: localized pain associated with neurologic
symptomsdue toneuroplexus involvement, vomitingdue togastric
compression, constipation, hydronephrosis, uremia due to renal
disorder, and ureteric compression. Izumi et al. [6] reported that
themost common symptomof retroperitoneal sarcomas is abdom-
inal pain (25.8%), followed by abdominal distension and palpable
mass, while 22.1% of the cases develop without symptoms. In
the present case, the ﬁrst symptoms were continuous abdominal
distension and respiratory discomfort lasting throughout the preg-
nancy without improvement, suggesting that themass existed and
grew during the pregnancy. Ultrasonographic examinations per-
formed as routine check-ups during the perinatal period did not
detect the retroperitoneal tumor in this case. Hence, it is recom-
mended that a transabdominal ultrasonographic examination (or
MRI if necessary) be performed in cases where a pregnant woman
complains of abdominal distention or respiratory discomfort.
We reviewed the literature on liposarcoma associated with
pregnancy and found 16 cases including ours. Their clinical courses
are summarized in Table 1 [1,3,7,8,10–18]. The mean age was 31
years (range, 15–44 years). Four cases of liposarcoma were dis-
covered during the ﬁrst trimester, 10 during the second or third
trimester, and 2 within the 1 year postnatal period. Only 2 patients
diagnosed in theﬁrst trimesterwere surgically treatedduringpreg-
nancy; in all other cases, surgery was performed after delivery.
Liposarcoma is classiﬁed into ﬁve histological subtypes:
well-differentiated, round-cell, myxoid, pleomorphic, and de-
differentiated (WHO classiﬁcation, 2002). There were 8 cases of
myxoid type and 4 cases of well-differentiated type, both of which
were classiﬁed as low-grade. Twelve cases were large tumors
exceeding 15 cm in diameter. According to the reports, surgerywas
the only treatment given during pregnancy; however, radiother-
apy to the lower extremity after delivery [7] and chemotherapy
in combination of mesna, doxorubisin and ifosfamid after surgi-
cal excision [8] have been reported. In terms of prognosis, out of
the 4 patients diagnosed in the ﬁrst trimester, 2 survived following
surgery under general anesthesia at 13thweek of pregnancy. How-
ever, all patients for whom surgery was performed after delivery
died. Therefore, surgical resection should be considered as soon as
possible, even if the initial diagnosis is made during pregnancy.
The effect of pregnancy on tumors is a major concern. In
our patient, a relationship existed between tumor growth and
pregnancy, and immunostaining was ER-positive. Cantin and
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Table 1
Clinicopathological characteristics of pregnancy-associated liposarcoma.
Author Age complaint Gestation at
diagnosis (W)
Location Surgery Tumor subtype Size (Weight) Prognosis
Pierandrea D.J. et al. [1] 41 Weight loss 34 Retroperitoneum 36 weeks of
gestation
concurrently with
CS
Myxoid 23 cm Died after 8
months
Jeng C-J. et al. [3] 33 Unknown 12 Retroperitoneum 36 weeks of
gestation
concurrently with
CS
Myxoid 25×20 cm Recurrence after 4
months postop.
Matsuda S.
et al. [7]
28 Pain in left thigh 29 Left thigh 5 weeks after CS at
33 weeks of
gestation
Myxoid 15×10×5 cm Free of disease 5
years postop.
34 Palpable mass 20 Right thigh 7 weeks after ID at
33 weeks of
gestation
Myxoid 15×13 cm Free of disease 4
years postop.
Tebes S. et al. [8] 22 Abdominal pain 13 Retroperitoneum 3 weeks after VD at
29 weeks of
gestation
Pleomorphic 20 cm Died after 2
months
Foruhan B. [10] 28 None 28 Retroperitoneum 38 weeks of
gestation
concurrently with
CS
Myxoid 30 cm (2.678kg) Free of disease 18
months postop.
Yamamoto
T. et al. [11]
29 Palpable mass 29 Right thigh none (chemoradio-
therapy after
CS)
Myxoid 8×8×5 cm Remission 13
months postop.
44 Palpable mass 22 Left thigh 6 weeks after CS at
32 weeks of
gestation
Well-differentiated 15×12×8 cm Free of disease 5
years postop.
Kurogouchi A. et al. [12] 30 Palpable mass 12 Retroperitoneum 13 weeks of
gestation (CS at 37
weeks of gestation)
Myxoid 34×14×14 cm Alive 4 years lataer
with operation for
reccurence
Lopes R.I. et al. [13] 33 None 13 Retroperitoneum 13 weeks of
gestation (CS at 37
weeks of gestation)
Well-differentiated 22×20
×20cm(3.75kg)
Free of disease 1
years postop.
Jafari K. et al. [14] 15 Chest pain 31–32 Mediastinum none (chemoradio-
therapy after
VD)
Anaplastic unknown Remission
Carrol F. et al. [15] 23 Respiratory
distress
32–33 Left pleura 32–33 weeks of
gestation
concurrently with
CS
Mixed-type 29×15×15+
21×12×
8cm(4.46kg)
Unknown
D-Garcia O.F. et al. [16] 35 Palpable mass 36 Retroperitoneum after delivery
(unspeciﬁed)
Well-differentiated 52×40×35 cm
(12.5 kg)
Free of disease 1
years postop.
Rouskova L. et al. [17] 32 Weight loss 34 Retroperitoneum 3 days after
delivery
Pleomorphic unknown Died after 1 month
Masuda T. et al. [18] 34 Unknown Diagnosis at
delivery
Retroperitoneum 3 months after
delivery
Myxoid 7.5×7.0×7.1 cm Free of disease 8
years postop.
Our case 34 Abdominal
distension
32weeks after
delivery
Retroperitoneum 9 months after
delivery
Well-differentiated 43×40
×13cm(7.2 kg)
Free of disease 3
years postop.
CS, cesarean section; ID, induced delivery; VD, vaginal delivery.
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Fig. 3. Hematoxylin and Eosin staining showing some lipoblasts with nuclear atypia (arrow) revealed a well-differentiated liposarcoma. A×40, B×200.
Fig. 4. Immunostaining revealed resected specimen was ER positive (10∼20%) (arrow). A×200, B×400.
McNeer [2] determined that pregnancy does not adversely affect
the prognosis of the tumor. However, they suggested that an
estrogen–progesterone environment possibly has a favorable inﬂu-
ence on the natural history of sarcoma, and the value of additive
hormone therapy in themanagement ofmetastatic sarcoma should
be explored. Matsuda et al. [7] reported that soft tissue sarcoma
can grow rapidly during pregnancy. Xiao-Qiu Li et al. [9] who ana-
lyzed 120 soft tissue sarcomas including 31 liposarcomas for ER
expression reported that neither gender nor age have a signiﬁcant
inﬂuence on the ER expression status, but further studies to assess
the hormonal dependency of ER-positivemesenchymal neoplasms
and potential therapeutic applications would be of clinicopatho-
logical signiﬁcance. Retroperitoneal liposarcoma associated with
pregnancy is an extremely rare occurrence, and no case inves-
tigating hormone receptors has been reported in the literature.
Surgical resection isunquestionably theﬁrst choiceof treatment for
retroperitoneal liposarcoma, but a complete resection can some-
times be impossible due to the volume and depth of invasion of
tumor. Therefore, additional therapy for liposarcoma is important
to improve prognosis; thus, this report highlights the need for fur-
ther research into hormone therapy.
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